Experienced in Monoclonal Gammopathy of Undetermined Significance (MGUS)

Murielle E. Roussel

CHU Purpan
Toulouse, FR 
Experienced in Monoclonal Gammopathy of Undetermined Significance (MGUS)
CHU Purpan
Toulouse, FR 
OverviewLocationsClinical Research

Overview

Murielle Roussel practices in Toulouse, France. Ms. Roussel is rated as an Experienced expert by MediFind in the treatment of Monoclonal Gammopathy of Undetermined Significance (MGUS). Her top areas of expertise are Multiple Myeloma, Primary Amyloidosis, Cardiac Amyloidosis, Bone Marrow Transplant, and Tissue Biopsy.

Her clinical research consists of co-authoring 106 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 2 articles in the study of Monoclonal Gammopathy of Undetermined Significance (MGUS).

Gender
Female

Locations

CHU Purpan
Toulouse, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

Front-line Therapy With Carfilzomib, Lenalidomide, and Dexamethasone (CRd) Induction Followed by Autologous Stem Cell Transplantation, CRd Consolidation and Lenalidomide Maintenance in Newly Diagnosed Multiple Myeloma Patients ≤65 Years Old
Front-line Therapy With Carfilzomib, Lenalidomide, and Dexamethasone (CRd) Induction Followed by Autologous Stem Cell Transplantation, CRd Consolidation and Lenalidomide Maintenance in Newly Diagnosed Multiple Myeloma Patients ≤65 Years Old
Enrollment Status: Completed
Publish Date: January 27, 2025
Intervention Type: Drug
Study Drug: Carfilzomib/Lenalidomide/Dexamethasone
Study Phase: Phase 2
IFM 2014-02 Study: A Randomized Phase III Study of Bortezomib-Melphalan 200 Conditioning Regimen Versus Melphalan 200 for Frontline Transplant Eligible Patients With Multiple Myeloma
IFM 2014-02 Study: A Randomized Phase III Study of Bortezomib-Melphalan 200 Conditioning Regimen Versus Melphalan 200 for Frontline Transplant Eligible Patients With Multiple Myeloma
Enrollment Status: Completed
Publish Date: May 23, 2022
Intervention Type: Drug
Study Drugs: Bortezomib-Melphalan, Melphalan
Study Phase: Phase 3
A Multicenter Open Label Phase 2 Study of Carfilzomib Weekly Plus Melphalan and Prednisone in Untreated Symptomatic Elderly Multiple Myeloma
A Multicenter Open Label Phase 2 Study of Carfilzomib Weekly Plus Melphalan and Prednisone in Untreated Symptomatic Elderly Multiple Myeloma
Enrollment Status: Unknown
Publish Date: August 27, 2020
Intervention Type: Drug
Study Drug: Carfilzomib
Study Phase: Phase 2
View 2 Less Clinical Trials

106 Total Publications

The Impact of Anti-CD38 Monoclonal Antibodies in Frontline Therapy for Patients With Newly Diagnosed Multiple Myeloma: Real-Life Results From the EMMY Study.
The Impact of Anti-CD38 Monoclonal Antibodies in Frontline Therapy for Patients With Newly Diagnosed Multiple Myeloma: Real-Life Results From the EMMY Study.
Journal: Clinical lymphoma, myeloma & leukemia
Published: July 03, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Roussel's expertise for a condition
ConditionClose
    View All 16 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile